EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Cervical yolk sac tumor: a case report and literature review

Ming Wang, Shuiqing Xu, Yang Zhan, Bei Fan, Yumei Wu

Frontiers in Oncology · 12.03.2026 · 16

DOI: 10.3389/fonc.2026.1782181 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 12.03.2026. Verfasst von Ming Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Ho…. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Yolk sac tumor (YST) is the third most common highly malignant germ cell tumor, predominantly arising from the ovary and testis. The standard treatment for ovarian YST is surgery combined with BEP (bleomycin, etoposide, and cisplatin) chemotherapy in which bleomycin has a cumulative lifetime dose and pulmonary toxicity. Advancements in treatment have yielded favorable prognoses for YST patients. Here, we present the clinical, imaging, pathological features, and individualized treatment of a case of primary cervical YST which is extremely rare in previous reports. Case report A 46-year-old female patient with primary cervical YST received neoadjuvant chemotherapy(1 cycle of paclitaxel+carboplatin, 2 cycles of BEP), radical surgery and 4 cycle of adjuvant BEP chemotherapy. The patient achieved complete remission after initial treatment but developed disease recurrence shortly thereafter, with confirmed BEP resistance. Salvage treatment with TC (albumin-bound paclitaxel and carboplatin) combined with bevacizumab was then administered, leading to a durable complete response; the patient subsequently received bevacizumab as maintenance therapy.

Conclusions

YST of the cervix is extremely rare. This article reviews the clinical characteristics, treatment, and survival of advanced cervical YST. In addition, the complete response of this patient provides a new option for patients with recurrent and metastatic cervical YST, and TC regimen combined with VEGF inhibitors is expected to serve as a salvage treatment.

Schlagwörter

Stichwörter der Autor:innen

alpha-fetoproteinantineoplastic combined chemotherapy protocolscervix neoplasmsgerm cell tumorsyolk sac tumor

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.
  • Department of Pathology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.

Zitieren

APA

Wang, M., Xu, S., Zhan, Y., Fan, B., & Wu, Y. (2026). Cervical yolk sac tumor: a case report and literature review. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1782181

Vancouver

Wang M, Xu S, Zhan Y, Fan B, Wu Y. Cervical yolk sac tumor: a case report and literature review. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1782181

BibTeX
@article{Wang2026,
  author = {Wang, Ming and Xu, Shuiqing and Zhan, Yang and Fan, Bei and Wu, Yumei},
  title = {Cervical yolk sac tumor: a case report and literature review},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1782181}
}
Kostenlos starten →